VIVUS, Inc. (NASDAQ: VVUS) (the “Company”), a specialty
pharmaceutical company committed to the development and
commercialization of innovative therapies focusing on treatments
for patients with serious unmet medical needs, today reported
financial results for the quarter ended June 30, 2019 and provided
a business update.
“We recently initiated a variety of programs
designed to improve patient access to Qsymia and PANCREAZE.
The initial response to the Qsymia Advantage Program, while early,
has been positive, accounting for 8% of second quarter
prescriptions after just 4 months of this platform’s launch,” said
John Amos, VIVUS’ Chief Executive Officer. “We believe that
this platform is an important component of our strategy to realize
the full potential of Qsymia, as our data show that patients
actually fill 92% of Qsymia Advantage Program prescriptions
compared with 65% of prescriptions issued through retail
pharmacies. Our PANCREAZE sales force has been fully implemented
with a revised compensation program that we believe will help
support our dedicated sales representatives. We remain focused on
expanding the market for both Qsymia and PANCREAZE by optimizing
both traditional and innovative sales strategies that leverage our
field force capabilities as well as online and social media
opportunities. In addition, we are pleased to announce that we have
reduced the cost to patients to provide greater access to these
products that we believe have significant potential to provide
meaningful lifestyle improvements.”
Recent Business Highlights
- Announced Approval of Qsymia® in the Republic of
KoreaIn August 2019, VIVUS announced that its Korean
marketing partner, Alvogen Malta Operations (ROW) Ltd, has obtained
marketing approval for Qsymia (phentermine and topiramate
extended-release) from the South Korea Ministry of Food and Drug
Safety (MFDS). VIVUS will receive a milestone payment associated
with the approval and remain eligible for future commercial
milestones and royalties on net revenues.
- Launch of Online Platform to Improve Patient Access to
QsymiaIn June 2019, VIVUS launched an e-medicine platform
that enables patients with a prescription for Qsymia to purchase
the medication online and have their orders delivered directly to
their homes. The online ordering platform is another component of
the Qsymia Advantage Program, which is designed to improve patient
access to Qsymia.
- Initiated Phase Four Safety and Efficacy Study of
Qsymia in Obese AdolescentsIn May 2019, the first patient
was enrolled in VIVUS’ Phase four clinical study designed to
evaluate the safety and efficacy of Qsymia®
(phentermine and topiramate extended-release) capsules CIV in obese
adolescents between the ages of 12 and 17 years. The Centers for
Disease Control and Prevention estimates that nearly 21 percent of
adolescents ages 12 to 19 years are obese. A study conducted
by the World Health Organization found that obesity in children
ages five to 19 years has risen ten-fold in the past four decades
and estimates that more children globally will be overweight rather
than underweight by 2022.
- Amended its Contract Manufacturing Agreement to Supply
Current and Future Demand for PANCREAZEIn June 2019, VIVUS
amended its manufacturing and supply agreement with Nordmark
Arzneimittel GmbH & Co. KG for PANCREAZE. The amended agreement
covers a ten-year initial term and may be renewed for additional
five-year periods, the first at VIVUS’ option and by mutual
agreement thereafter.
- Launched the PANCREAZE® Patient
Assistance ProgramIn May 2019, VIVUS announced a
partnership to facilitate access to PANCREAZE (pancrelipase)
Delayed Release Capsules for uninsured or underinsured patients
with exocrine pancreatic insufficiency (EPI) that meet applicable
eligibility criteria. PANCREAZE is available to eligible
patients through the VIVUS Health Platform and the PANCREAZE
Advantage Program integrated with HarborPath Direct’s SuccorRx™
Patient Assistance Program (PAP) platform.
2019 Second Quarter vs 2019 First
Quarter Financial Results
Revenue consisted of the following:
|
(In thousands)Three Months
Ended |
|
June 30,2019 |
|
March 31,2019 |
Qsymia net product revenue |
$ |
9,994 |
|
$ |
8,423 |
PANCREAZE net product revenue |
|
5,110 |
|
|
5,074 |
Supply revenue |
|
1,780 |
|
|
1,604 |
Royalty revenue |
|
1,506 |
|
|
1,045 |
Total revenue |
$ |
18,390 |
|
$ |
16,146 |
|
|
|
|
|
|
Total revenue for the second and first quarters
of 2019 was $18.4 million and 16.1 million, an increase of 14%.
Qsymia net product revenue was $10.0 million and
$8.4 million in the second and first quarters of 2019,
respectively. Shipments were approximately 87,000 and 75,000 units
in the second and first quarters of 2019, respectively. The
Company made a number of changes to the Qsymia business in an
effort to improve commercial performance, primarily allowing
patients to migrate from a traditional retail pharmacy model to the
Qsymia Advantage Program that is expected to improve access to
Qsymia through, among other things, direct-to-patient distribution
and improved pricing. The Company anticipates that this transfer,
which started in February of 2019 with the re-launch, will be one
of the key drivers of brand performance in the second half of 2019
and full year 2020. In the second quarter of 2019, approximately
86,000 prescriptions were dispensed as compared to 82,000 in the
first quarter of 2019. During the second quarter, 8% of these
scripts were dispensed through the Qsymia Advantage Program’s
Direct-to-Patient model, up from 2% in the first quarter of
2019.
PANCREAZE net product revenue was $5.1 million
in both the second and first quarters of 2019. During the second
and first quarters of 2019, the Company shipped approximately
27,000 and 26,000 units of PANCREAZE, respectively. VIVUS now has a
dedicated 10-person sales force, sampling program, full patient
support program, a plan for investigator-sponsored trials in
oncology, a digital marketing campaign strategy, along with a
number of other enhancements.
Total cost of goods sold excluding amortization
was $4.4 million and $4.3 million in the second and first quarters
of 2019, respectively. The growth was primarily due to the growth
in revenue.
Amortization of intangible assets was $3.6
million in both the second and first quarters of 2019. The amount
primarily consisted of amortization expense of costs capitalized
related to the acquisition of PANCREAZE.
Selling, general and administrative expense was
$10.1 million and $9.8 million for the second and first quarters of
2019, respectively and included selling and marketing expense of
$4.6 million and $4.5 million, respectively. VIVUS expects
selling, general and administrative expenses to fluctuate with
business development activities.
Research and development expense was $2.4
million and $2.5 million in the second and first quarters of 2019,
respectively. In 2019, research and development efforts primarily
consisted of activities related to the Qsymia adolescent and
efficacy study (OB-0403), PANCREAZE post-marketing requirements
assumed from Janssen and ongoing PANCREAZE product improvement
initiatives.
Total interest and other expense was $3.9
million in both the second and first quarters of 2019,
respectively. On an annual basis, VIVUS will make cash
interest payments of approximately $19.6 million on its convertible
and senior secured notes.
Net loss for the second and first quarters of
2019 was $5.9 million and $7.9 million, respectively. Cash, cash
equivalents and available-for-sale securities were $94.4 million at
June 30, 2019.
Recurring non-GAAP EBITDA for the second and
first quarters of 2019 was $2.1 million and $0.1 million,
respectively.
Conference Call Details
VIVUS will hold a conference call and an
audio webcast to provide a business update and to discuss second
quarter 2019 financial results today, August 6, 2019,
beginning at 4:30 PM Eastern Time. Investors may listen to
this call by dialing toll-free 1-877-359-2916 in
the U.S. and 1-224-357-2386 from outside
the U.S. The audience passcode is 5386769. A
webcast replay will be available for 30 days and may be accessed
at http://ir.vivus.com/events-and-presentations.
About Qsymia
Qsymia is approved in the U.S. and is indicated
as an adjunct to a reduced-calorie diet and increased physical
activity for chronic weight management in adults with an initial
body mass index (BMI) of 30 kg/m2 or greater (obese) or 27
kg/m2 or greater (overweight) in the presence of at least one
weight-related medical condition such as high blood pressure, type
2 diabetes, or high cholesterol.
The effect of Qsymia on cardiovascular morbidity
and mortality has not been established. The safety and
effectiveness of Qsymia in combination with other products intended
for weight loss, including prescription and over-the-counter drugs,
and herbal preparations, have not been established.
For more information about Qsymia, please
visit www.Qsymia.com.
Important Safety Information for
Qsymia
Qsymia® (phentermine and topiramate
extended-release) capsules CIV is contraindicated in pregnancy; in
patients with glaucoma; in hyperthyroidism; in patients receiving
treatment or within 14 days following treatment with monoamine
oxidase inhibitors; or in patients with hypersensitivity to
sympathomimetic amines, topiramate, or any of the inactive
ingredients in Qsymia.
Qsymia can cause fetal harm. Females of
reproductive potential should have a negative pregnancy test before
treatment and monthly thereafter and use effective contraception
consistently during Qsymia therapy. If a patient becomes
pregnant while taking Qsymia, treatment should be discontinued
immediately, and the patient should be informed of the potential
hazard to the fetus.
The most commonly observed side effects in
controlled clinical studies, 5% or greater and at least 1.5 times
placebo, include paraesthesia, dizziness, dysgeusia, insomnia,
constipation, and dry mouth.
About PANCREAZE
PANCREAZE is a prescription medicine used to
treat people who cannot digest food normally because their pancreas
does not make enough enzymes due to cystic fibrosis or other
conditions. PANCREAZE may help your body use fats, proteins,
and sugars from food. PANCREAZE contains a mixture of
digestive enzymes including lipases, proteases, and amylases from
pig pancreas. PANCREAZE is safe and effective in children
when taken as prescribed by your doctor.
Important Safety Information for PANCREAZE
What is the most important information I should know
about PANCREAZE?
- PANCREAZE may increase your chance of having a serious, rare
bowel disorder called fibrosing colonopathy that may require
surgery.
- The risk of having this condition may be reduced by following
the dosing instructions that your healthcare provider gave
you.
Call your doctor right away if you have any unusual
or severe stomach area (abdominal) pain, bloating,
trouble passing stool (having bowel movements), nausea, vomiting,
or diarrhea.
Take PANCREAZE exactly as prescribed by your doctor. Do
not take more or less PANCREAZE than directed by your doctor.
What are the possible side effects of
PANCREAZE?
PANCREAZE may cause serious side effects,
including:
- A rare bowel disorder called fibrosing
colonopathy.
- Irritation of the inside of your mouth.
This can happen if PANCREAZE is not swallowed
completely.
- Increase in blood uric acid levels. This
may cause worsening of swollen, painful joints (gout) caused by an
increase in your blood uric acid levels.
- Allergic reactions including trouble with
breathing, skin rashes, or swollen lips.
Call your doctor right away if you have any of these
symptoms.
The most common side effects include pain in your stomach
(abdominal pain) and gas.
Other possible side effects: PANCREAZE and other
pancreatic enzyme products are made from the pancreas of pigs, the
same pigs people eat as pork. These pigs may carry viruses.
Although it has never been reported, it may be possible for a
person to get a viral infection from taking pancreatic enzyme
products that come from pigs.
These are not all the side effects of PANCREAZE. Talk to
your doctor about any side effect that bothers you or does not go
away.
You may report side effects to FDA at 1-800-FDA-1088
or www.fda.gov/medwatch.
What should I tell my doctor before taking
PANCREAZE?
Tell your doctor if you:
- are allergic to pork (pig) products.
- have a history of blockage of your intestines, or scarring or
thickening of your bowel wall (fibrosing colonopathy).
- have gout, kidney disease, or high blood uric acid
(hyperuricemia).
- have trouble swallowing capsules.
- have any other medical condition.
- are pregnant or plan to become pregnant.
- are breast-feeding or plan to breast-feed.
Tell your doctor about all the medicines you
take, including prescription and nonprescription
medicines, vitamins, and herbal supplements.
The Product Information and Medication Guide for PANCREAZE is
available at www.pancreaze.com.
About STENDRA/SPEDRA
(Avanafil)
STENDRA® (avanafil) is approved in the U.S.
by the FDA for the treatment of erectile
dysfunction. Metuchen Pharmaceuticals LLC has exclusive
marketing rights to STENDRA in the U.S., Canada, South
America and India.
STENDRA is available through retail and mail
order pharmacies.
SPEDRA™, the trade name for avanafil in the EU,
is approved by the EMA for the treatment of erectile dysfunction in
the EU. VIVUS has granted an exclusive license to
the Menarini Group through its
subsidiary Berlin-Chemie AG to commercialize and promote
SPEDRA for the treatment of erectile dysfunction in over 40
European countries plus Australia and New Zealand.Avanafil is
licensed from Mitsubishi Tanabe Pharma
Corporation (MTPC). VIVUS owns worldwide
development and commercial rights to avanafil for the treatment of
sexual dysfunction, with the exception of certain Asian-Pacific Rim
countries. VIVUS is in discussions with other parties
for the commercialization rights to its remaining territories.
For more information about STENDRA, please
visit www.STENDRA.com.
Important Safety Information for
STENDRA
STENDRA® (avanafil) is prescribed to treat
erectile dysfunction (ED).
Do not take STENDRA if you take nitrates, often
prescribed for chest pain, as this may cause a sudden, unsafe drop
in blood pressure.
Discuss your general health status with your
healthcare provider to ensure that you are healthy enough to engage
in sexual activity. If you experience chest pain, nausea, or
any other discomforts during sex, seek immediate medical help.
STENDRA may affect the way other medicines work.
Tell your healthcare provider if you take any of the
following; medicines called HIV protease inhibitors, such as
ritonavir (Norvir®), indinavir (Crixivan®), saquinavir
(Fortavase® or Invirase®) or atazanavir (Reyataz®); some types
of oral antifungal medicines, such as ketoconazole (Nizoral®), and
itraconazole (Sporanox®); or some types of antibiotics, such as
clarithromycin (Biaxin®), telithromycin (Ketek®), or
erythromycin.
In the rare event of an erection lasting more
than 4 hours, seek immediate medical help to avoid long-term
injury.
In rare instances, men taking PDE5 inhibitors
(oral erectile dysfunction medicines, including STENDRA) reported a
sudden decrease or loss of vision. It is not possible to
determine whether these events are related directly to these
medicines or to other factors. If you experience sudden
decrease or loss of vision, stop taking PDE5 inhibitors, including
STENDRA, and call a doctor right away.
Sudden decrease or loss of hearing has been
rarely reported in people taking PDE5 inhibitors, including
STENDRA. It is not possible to determine whether these events
are related directly to the PDE5 inhibitors or to other factors.
If you experience sudden decrease or loss of hearing, stop
taking STENDRA and contact a doctor right away. If you have
prostate problems or high blood pressure for which you take
medicines called alpha blockers or other anti-hypertensives, your
doctor may start you on a lower dose of STENDRA.
Drinking too much alcohol when taking STENDRA
may lead to headache, dizziness, and lower blood pressure.
STENDRA in combination with other treatments for
ED is not recommended.
STENDRA does not protect against sexually
transmitted diseases, including HIV.
The most common side effects of STENDRA are
headache, flushing, runny nose and congestion.Please see full
patient prescribing information for STENDRA (50 mg, 100 mg, 200 mg)
tablets.
About VIVUS
VIVUS is a specialty pharmaceutical company
committed to the development and commercialization of innovative
therapies that focus on advancing treatments for patients with
serious unmet medical needs. For more information about the
Company, please visit www.vivus.com.
Forward-Looking Statements
Certain statements in this press release are
forward-looking within the meaning of the Private Securities
Litigation Reform Act of 1995 and are subject to risks,
uncertainties and other factors, including risks and uncertainties
related to our ability to execute on our business strategy to
enhance long-term stockholder value; risks and uncertainties
related to our ability to address our outstanding balance of the
convertible notes due in May 2020; risks and uncertainties related
to our expected future revenues, operations and expenditures; risks
and uncertainties related to our ability to identify and acquire
cash flow generating assets and opportunities; risks and
uncertainties related to the timing, strategy, tactics and success
of the marketing and sales of PANCREAZE, including our ability to
improve patient access to PANCREAZE; risks and uncertainties
related to our commercialization of PANCREAZE as a new product and
our recently changed management team initiating the
commercialization of PANCREAZE; risks and uncertainties related to
our, or our current or potential partner's, ability to successfully
commercialize Qsymia, including our ability to improve patient and
physician access to Qsymia; risks and uncertainties related to the
impact of promotional programs for Qsymia on our net product
revenue and net income (loss) in future periods; risks and
uncertainties related to our ability to sell through the Qsymia
retail pharmacy network and the Qsymia Advantage Program; risks and
uncertainties related to our ability to successfully develop or
acquire a proprietary formulation of tacrolimus; risks and
uncertainties related to our ability to identify, acquire and
develop new product pipeline candidates; risks and uncertainties
related to our ability to demonstrate through clinical testing the
quality, safety, and efficacy of our current or future
investigational drug candidates or approved products; risks and
uncertainties related to the timing, strategy, tactics and success
of the launches and commercialization of STENDRA/SPEDRA (avanafil)
by our current or potential collaborators; risks and uncertainties
related to our ability to successfully complete on acceptable
terms, and on a timely basis, avanafil partnering discussions for
territories under our license with MTPC in which we do not have a
commercial collaboration; risks and uncertainties related to our
ability to work with FDA to significantly reduce or remove the
requirements of the clinical post-approval cardiovascular outcomes
trial (“CVOT”); risks and uncertainties related to our dialog with
the European Medicines Agency (“EMA”) or certain member states on a
decentralized basis relating to the resubmission of an application
for the grant of a marketing authorization, the timing and scope of
such resubmission, the assessment by European health
authorities of the application for marketing authorization, and
ultimately the decision of such European health authorities whether
to grant marketing authorization for Qsymia in the EU; risks and
uncertainties related to the failure to obtain FDA or
foreign authority clearances or approvals and noncompliance
with FDA or foreign authority regulations; and risks and
uncertainties related to our ability to successfully integrate
changes to our Board of Directors and senior management team. These
risks and uncertainties could cause actual results to differ
materially from those referred to in these forward-looking
statements. The reader is cautioned not to rely on these
forward-looking statements. Investors should read the risk
factors set forth in VIVUS’ Form 10-K for the year ended December
31, 2018 as filed on February 26, 2019, and periodic reports filed
with the Securities and Exchange Commission. VIVUS does not
undertake an obligation to update or revise any forward-looking
statements.
|
|
VIVUS, Inc. |
Investor Relations: Lazar Partners |
Mark Oki |
David Carey |
Chief Financial Officer |
dcarey@lazarpartners.com |
oki@vivus.com |
212-867-1768 |
650-934-5200 |
|
|
|
VIVUS, INC.CONDENSED CONSOLIDATED
BALANCE SHEETS(In thousands, except par
value)
|
|
|
|
|
|
|
June 30, |
|
December 31, |
|
2019 |
|
2018 |
ASSETS |
|
Unaudited |
|
|
|
Current assets: |
|
|
|
|
|
Cash and cash equivalents |
$ |
25,022 |
|
|
$ |
30,411 |
|
Available-for-sale securities |
|
69,344 |
|
|
|
80,838 |
|
Accounts receivable, net |
|
24,568 |
|
|
|
25,608 |
|
Inventories |
|
30,111 |
|
|
|
23,132 |
|
Prepaid expenses and other current assets |
|
6,970 |
|
|
|
7,538 |
|
Total current assets |
|
156,015 |
|
|
|
167,527 |
|
Property and equipment,
net |
|
306 |
|
|
|
341 |
|
Right-of-use assets |
|
1,323 |
|
|
|
— |
|
Intangible and other
non-current assets |
|
127,003 |
|
|
|
134,279 |
|
Total assets |
$ |
284,647 |
|
|
$ |
302,147 |
|
LIABILITIES AND STOCKHOLDERS’ DEFICIT |
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
Accounts payable |
$ |
3,800 |
|
|
$ |
8,921 |
|
Accrued and other liabilities |
|
34,384 |
|
|
|
33,044 |
|
Deferred revenue |
|
1,205 |
|
|
|
1,235 |
|
Current portion of lease liability |
|
710 |
|
|
|
— |
|
Current portion of long-term debt |
|
185,384 |
|
|
|
— |
|
Total current liabilities |
|
225,483 |
|
|
|
43,200 |
|
Long-term debt, net of current portion |
|
107,007 |
|
|
|
294,446 |
|
Deferred revenue, net of current portion |
|
3,738 |
|
|
|
4,290 |
|
Lease liability, net of current portion |
|
894 |
|
|
|
— |
|
Non-current accrued and other liabilities |
|
— |
|
|
|
234 |
|
Total liabilities |
|
337,122 |
|
|
|
342,170 |
|
Commitments and
contingencies |
|
|
|
|
|
Stockholders’ deficit: |
|
|
|
|
|
Preferred stock; $.001 par value; 5,000 shares authorized; no
shares issued and outstanding at June 30, 2019 and
December 31, 2018 |
|
— |
|
|
|
— |
|
Common stock; $.001 par value; 200,000 shares
authorized; 10,643 and 10,636 shares issued and outstanding at
June 30, 2019 and December 31, 2018, respectively |
|
11 |
|
|
|
11 |
|
Additional paid-in capital |
|
841,702 |
|
|
|
840,751 |
|
Accumulated other comprehensive loss |
|
201 |
|
|
|
(270 |
) |
Accumulated deficit |
|
(894,389 |
) |
|
|
(880,515 |
) |
Total stockholders’ deficit |
|
(52,475 |
) |
|
|
(40,023 |
) |
Total liabilities and stockholders’ deficit |
$ |
284,647 |
|
|
$ |
302,147 |
|
|
|
|
|
|
|
|
|
VIVUS, INC.CONDENSED CONSOLIDATED
STATEMENTS OF OPERATIONS(In thousands, except per
share data)(Unaudited)
|
|
|
|
|
|
|
Three Months Ended |
|
June 30, |
|
March 31, |
2019 |
2019 |
Revenue: |
|
|
|
|
|
Net product revenue |
$ |
15,104 |
|
|
$ |
13,497 |
|
Supply revenue |
|
1,780 |
|
|
|
1,604 |
|
Royalty revenue |
|
1,506 |
|
|
|
1,045 |
|
Total revenue |
|
18,390 |
|
|
|
16,146 |
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
Cost of goods sold (excluding amortization) |
|
4,377 |
|
|
|
4,308 |
|
Amortization of intangible assets |
|
3,638 |
|
|
|
3,638 |
|
Selling, general and administrative |
|
10,070 |
|
|
|
9,818 |
|
Research and development |
|
2,352 |
|
|
|
2,469 |
|
Total operating expenses |
|
20,437 |
|
|
|
20,233 |
|
|
|
|
|
|
|
Loss from operations |
|
(2,047 |
) |
|
|
(4,087 |
) |
|
|
|
|
|
|
Interest expense and other expense, net |
|
3,880 |
|
|
|
3,870 |
|
Loss before income taxes |
|
(5,927 |
) |
|
|
(7,957 |
) |
Provision for income
taxes |
|
8 |
|
|
|
(8 |
) |
Net loss |
$ |
(5,935 |
) |
|
$ |
(7,949 |
) |
|
|
|
|
|
|
Basic and diluted net loss per
share: |
$ |
(0.56 |
) |
|
$ |
(0.75 |
) |
Shares used in per share
computation: |
|
|
|
|
|
Basic and diluted |
|
10,640 |
|
|
|
10,637 |
|
|
|
VIVUS, INC.GAAP to
NON-GAAP RECONCILIATIONNET LOSS to
EBITDA(In
thousands)(Unaudited)
A reconciliation between net loss on a GAAP
basis and non-GAAP EBITDA is as follows:
|
Three Months Ended |
|
June 30,2019 |
|
March 31,2019 |
Net loss |
$ |
(5,935 |
) |
|
$ |
(7,949 |
) |
Adjustments: |
|
|
|
|
|
Interest expense and other expense, net |
|
3,880 |
|
|
|
3,870 |
|
Depreciation of fixed assets |
|
37 |
|
|
|
37 |
|
Amortization of intangible assets |
|
3,638 |
|
|
|
3,638 |
|
Share-based compensation expense |
|
467 |
|
|
|
468 |
|
Provision for income taxes |
|
8 |
|
|
|
(8 |
) |
Non-GAAP EBITDA and Non-GAAP recurring EBITDA |
$ |
2,095 |
|
|
$ |
56 |
|
|
|
|
|
|
|
|
|
Use of Non-GAAP Financial Measures
We supplement our condensed consolidated
financial statements presented on a GAAP basis by providing an
additional measure which is considered non-GAAP under applicable
SEC rules. We believe that the disclosure of this non-GAAP measure
provides investors with additional information that reflects the
basis upon which our management assesses and operates our business.
This non-GAAP financial measure is not in accordance with GAAP and
should not be viewed in isolation or as a substitute for GAAP net
loss and is not a substitute for, or superior to, measures of
financial performance performed in conformity with GAAP.
We define non-GAAP EBITDA as net loss before
interest expense and other expense, depreciation of fixed assets,
amortization of intangible assets, share-based compensation expense
and provision for or benefit from income taxes. We define non-GAAP
Recurring EBITDA as non-GAAP EBITDA adjusted for certain
non-recurring revenues and expenses, such as non-recurring
milestone revenues, non-recurring restructuring and transaction
costs and the one-time impact of changes in accounting estimates or
the impact of new accounting standards. Management believes that
non-GAAP EBITDA is a meaningful indicator of our performance and
provides useful information to investors regarding our results of
operations and financial condition.
VIVUS (NASDAQ:VVUS)
Historical Stock Chart
From Mar 2024 to Apr 2024
VIVUS (NASDAQ:VVUS)
Historical Stock Chart
From Apr 2023 to Apr 2024